Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

OBJECTIVE: Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ran, Ran, Huang, Wenfa, Liu, Yaxin, Shao, Lin, Liu, Xiaoran, Niu, Yunyun, Kong, Weiyao, Bo, Shiping, Rugo, Hope S, Lu, Sijia, Li, Huiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245474/
https://www.ncbi.nlm.nih.gov/pubmed/32547071
http://dx.doi.org/10.2147/OTT.S240990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245474/
https://www.ncbi.nlm.nih.gov/pubmed/32547071
http://dx.doi.org/10.2147/OTT.S240990

Ejemplares similares